PMID- 9157074
OWN - NLM
STAT- MEDLINE
DCOM- 19970520
LR  - 20191024
IS  - 0167-6997 (Print)
IS  - 0167-6997 (Linking)
VI  - 14
IP  - 4
DP  - 1996
TI  - Phase I trial of recombinant platelet factor 4 (rPF4) in patients with advanced 
      colorectal carcinoma.
PG  - 387-9
AB  - BACKGROUND: Recombinant platelet factor 4 (rPF4) is a naturally occurring protein 
      found in platelet alpha granules that can inhibit angiogenesis. METHODS: In this 
      Phase I trial, 9 patients with metastatic colorectal cancer who had failed 5-FU 
      treatment received rPF4 at doses ranging from 0.3 to 3.0 mg/kg via 30-minute 
      infusion. Three additional patients were treated with the 3 mg/kg dose over a 
      6-hour period of infusion. RESULTS: The only toxicity encountered was mild leg 
      twitching in 2/3 patients treated with the 6-hour infusion. One patient with a 
      history of phlebitis developed a lower extremity deep venous thrombosis after the 
      first dose of rPF4. A mild rise in fibrinogen level was noted in several 
      patients. Of the 11 evaluable patients, there were no clinical responses to 
      treatment. CONCLUSIONS: rPF4 is well tolerated at the doses and schedules tested. 
      No clinical responses were observed. Prolonged infusion schedules should be 
      investigated.
FAU - Belman, N
AU  - Belman N
AD  - Department of Medicine, M.S. Hershey Medical Center, Pennsylvania State 
      University, Hershey 17033, USA.
FAU - Bonnem, E M
AU  - Bonnem EM
FAU - Harvey, H A
AU  - Harvey HA
FAU - Lipton, A
AU  - Lipton A
LA  - eng
PT  - Clinical Trial
PT  - Clinical Trial, Phase I
PT  - Journal Article
PL  - United States
TA  - Invest New Drugs
JT  - Investigational new drugs
JID - 8309330
RN  - 0 (Coagulants)
RN  - 37270-94-3 (Platelet Factor 4)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Coagulants/*administration & dosage/therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Female
MH  - Humans
MH  - Infusions, Intravenous
MH  - Male
MH  - Middle Aged
MH  - Platelet Factor 4/*adverse effects/therapeutic use
EDAT- 1996/01/01 00:00
MHDA- 1996/01/01 00:01
CRDT- 1996/01/01 00:00
PHST- 1996/01/01 00:00 [pubmed]
PHST- 1996/01/01 00:01 [medline]
PHST- 1996/01/01 00:00 [entrez]
AID - 10.1007/BF00180815 [doi]
PST - ppublish
SO  - Invest New Drugs. 1996;14(4):387-9. doi: 10.1007/BF00180815.